PT - JOURNAL ARTICLE AU - Luke Tzu-Chi Liu AU - Cheng-Hsun Chiu AU - Nan-Chang Chiu AU - Boon-Fatt Tan AU - Chien-Yu Lin AU - Hao-Yuan Cheng AU - Meei-Yun Lin AU - Chia-En Lien AU - Charles Chen AU - Li-Min Huang TI - Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial AID - 10.1101/2022.03.14.22272325 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.14.22272325 4099 - http://medrxiv.org/content/early/2022/03/15/2022.03.14.22272325.short 4100 - http://medrxiv.org/content/early/2022/03/15/2022.03.14.22272325.full AB - Background MVC-COV1901 is a subunit SARS-CoV-2 vaccine based on the prefusion spike protein S-2P and adjuvanted with CpG 1018 and aluminum hydroxide. Although MVC-COV1901 has been licensed for emergency use for adults in Taiwan, the safety and immunogenicity of MVC-COV1901 in adolescents remained unknown. As young people play an important role in SARS-CoV-2 transmission and epidemiology, a vaccine approved for adolescents and eventually, children, will be important in mitigating the COVID-19 pandemic.Methods This study is a prospective, double-blind, multi-center phase 2 trial evaluating the safety, tolerability and immunogenicity of two doses of the SARS-CoV-2 vaccine MVC-COV1901 in adolescents. Healthy adolescents from age of 12 to 17 years were recruited and randomly assigned (6:1) to receive two intramuscular doses of either MVC-COV1901 or placebo at 28 days apart. The primary outcomes were safety and immunogenicity from the day of first vaccination (Day 1) to 28 days after the second vaccination (Day 57), and immunogenicity of MVC COV1901 in adolescents as compared to young adult vaccinees in terms of neutralizing antibody titers and seroconversion rate. The secondary outcomes were safety and immunogenicity of MVC-COV1901 as compared to placebo in adolescents in terms of immunoglobulin titers and neutralizing antibody titers over the study period.Results Between July 21, 2021 and December 22, 2021, a total of 399 adolescent participants were included for safety evaluation after enrollment to receive at least one dose of either MVC-COV1901 (N=341) or placebo (N=58). Of these, 334 and 46 participants went on to receive two doses of either MVC-COV1901 or placebo, respectively, and were included in the per protocol set (PPS) for immunogenicity analysis. Adverse events were mostly mild and were similar in MVC-COV1901 and placebo groups. The most commonly reported adverse events were pain/tenderness and malaise/fatigue. All immunogenicity endpoints in the adolescent group were non-inferior to the endpoints seen in the young adult and placebo groups.Conclusions The safety and immunogenicity data presented here showed that MVC-COV1901 has similar safety profile and non-inferior immunogenicity in adolescents compared to young adults.ClinicalTrials.gov registration NCT04951388.Competing Interest StatementL. T.-C. L., C. E. L., M.-Y. L., H.-Y. C. and C. C. are employees of Medigen Vaccine Biologics Corporation and have received grants from the Taiwan Centers of Disease Control, Ministry of Health and Welfare. L.-M. H. declared no conflict of interest. All authors have reviewed and approved of the final version of the manuscript.Clinical TrialNCT04951388Funding StatementThis study was funded by Medigen Vaccine Biologics Corporation (MVC, the study sponsor) and Taiwan Centers for Disease Control (CDC), Ministry of Health and Welfare. MVC had a role in study design, data analysis, and data interpretation, but had no role in data collection, or writing of the clinical report. Taiwan CDC of the Ministry of Health and Welfare had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol and informed consent form were approved by Taiwan Food and Drug Administration (TFDA) and the ethics committees at the conducting sites: Mackay Memorial Hospital Hsinchu (Hsinchu City), Chang-Gung Memorial Hospital Linkou (New Taipei City), Mackay Memorial Hospital (Taipei City), National Taiwan University Hospital Hsinchu (Hsinchu City), and National Taiwan University Hospital (Taipei City).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript